Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127978761 | 12797876 | 1 | I | 20160728 | 20160801 | 20160930 | 20160930 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-063759 | BRISTOL MYERS SQUIBB | 80.44 | YR | F | Y | 0.00000 | 20160930 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127978761 | 12797876 | 1 | PS | METGLUCO | METFORMIN HYDROCHLORIDE | 1 | Oral | 250 MG, TID | Y | 20357 | 250 | MG | TID | ||||||
| 127978761 | 12797876 | 2 | SS | METGLUCO | METFORMIN HYDROCHLORIDE | 1 | Oral | 250 MG, BID | Y | 20357 | 250 | MG | BID | ||||||
| 127978761 | 12797876 | 3 | SS | SUREPOST | REPAGLINIDE | 1 | Oral | 0.25 MG, UNK | Y | 0 | .25 | MG | |||||||
| 127978761 | 12797876 | 4 | SS | SUREPOST | REPAGLINIDE | 1 | Oral | 0.125 MG, TID | Y | 0 | .125 | MG | TID | ||||||
| 127978761 | 12797876 | 5 | SS | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 9 IU, UNK | Y | 0 | 9 | IU | |||||||
| 127978761 | 12797876 | 6 | SS | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 15 IU, UNK | Y | 0 | 15 | IU | |||||||
| 127978761 | 12797876 | 7 | SS | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 21 IU, UNK | Y | 0 | 21 | IU | |||||||
| 127978761 | 12797876 | 8 | SS | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 9 IU, UNK | Y | 0 | 9 | IU | |||||||
| 127978761 | 12797876 | 9 | SS | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 21 IU, UNK | Y | 0 | 21 | IU | |||||||
| 127978761 | 12797876 | 10 | SS | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Subcutaneous | 5 IU, UNK | Y | 0 | 5 | IU | |||||||
| 127978761 | 12797876 | 11 | SS | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Subcutaneous | 7 IU, UNK | Y | 0 | 7 | IU | |||||||
| 127978761 | 12797876 | 12 | SS | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Subcutaneous | 3 IU, UNK | Y | 0 | 3 | IU |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127978761 | 12797876 | 1 | Diabetes mellitus |
| 127978761 | 12797876 | 3 | Diabetes mellitus |
| 127978761 | 12797876 | 5 | Diabetes mellitus |
| 127978761 | 12797876 | 10 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127978761 | 12797876 | LT |
| 127978761 | 12797876 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127978761 | 12797876 | Diarrhoea | |
| 127978761 | 12797876 | Hypoglycaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127978761 | 12797876 | 1 | 20160727 | 0 | ||
| 127978761 | 12797876 | 2 | 20160728 | 0 | ||
| 127978761 | 12797876 | 3 | 20160727 | 20160728 | 0 | |
| 127978761 | 12797876 | 4 | 20160728 | 20160729 | 0 | |
| 127978761 | 12797876 | 5 | 20160621 | 20160623 | 0 | |
| 127978761 | 12797876 | 6 | 20160623 | 20160629 | 0 | |
| 127978761 | 12797876 | 7 | 20160629 | 20160704 | 0 | |
| 127978761 | 12797876 | 8 | 20160704 | 20160714 | 0 | |
| 127978761 | 12797876 | 9 | 20160714 | 20160726 | 0 | |
| 127978761 | 12797876 | 10 | 20160621 | 20160623 | 0 | |
| 127978761 | 12797876 | 11 | 20160623 | 20160629 | 0 | |
| 127978761 | 12797876 | 12 | 20160629 | 20160704 | 0 |